Ipsen Deal History & Licensing Activity
Ipsen is a large pharma headquartered in France. Over the past three years, Ipsen has been involved in 5 licensing and acquisition transactions, with a primary focus on Antibodies (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
5
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Ipsen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Ipsen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Memo Therapeutics pipeline | Memo Therapeutics | Antibodies | Unknown | acquisition | Jul 15, 2026 |
| MDM2 blocker | Kartos | Small Molecules | Unknown | acquisition | Jul 11, 2026 |
| Memo Therapeutics midstage monoclonal antibody | Memo Therapeutics | Antibodies | Phase 2 | acquisition |
Ipsen Pipeline Focus
Therapeutic areas and modalities where Ipsen is most active based on deal history and clinical trial data.
Therapeutic Areas
Ipsen Strategic Signals
Key indicators of Ipsen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Ipsen Clinical Pipeline
Ipsen has 50 active clinical trials across 6 development phases.
18
Unknown
2
Not Applicable
1
Phase 4
8
Phase 1
10
Phase 2
11
Phase 3
See How Your Asset Matches Ipsen's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Ipsen Licensing & Deal Activity
Ipsen is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Ipsen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Ipsen include Solid Tumors (13 deals and trials), Mega Deals (10 deals and trials), CNS Disorders (5 deals and trials), and Hematological Malignancies (4 deals and trials). In terms of modality, Ipsen has shown particular interest in antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ipsen and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Ipsen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.